If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 1 - 10 of 36

A Phase 1, Multicenter, First-in-Human Study of DS-1471A in Subjects with Advanced Solid Tumors

Objective
The purpose of this study is to learn more about an investigational drug called DS-1471a. DS-1471a is an investigational drug that is not approved for your disease by health authorities, such as the U.S. Food and Drug Administration (FDA). It is being studied to see if it is safe and if your disease or medical condition improves while taking it.
Protocol No
DAIICHI-SANKYO-DS1471-079
Categories
Cancer, Lung, Gastrointestinal Cancers, Early Phase/Multiple Disease Site Cancers, Head and Neck Cancers, Thoracic Cancers

A Phase 1/2, Open-label, Multicenter, First-in-human Study of DS-3939a in Subjects with Advanced Solid Tumors

Objective
The purpose of this study is to learn more about an investigational drug called DS-3939a. DS-3939a is an investigational drug that is not approved for your disease. It is being studied to see if it is safe and if your disease or medical condition improves while taking it.
Protocol No
DAIICHI-SANKYO-DS3939-077
Categories
Cancer, Kidney, Skin Cancers, Stomach, Uterine, Lung, Other Urologic, Head and Neck Cancers, Esophagus, Thoracic Cancers, Ovary, Other Gastrointestinal, Sarcoma, Gastrointestinal Cancers, Prostate, Prostate and Urologic Cancers, Cervix, Gynecologic Cancers, Early Phase/Multiple Disease Site Cancers, Breast Cancers

Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)

Objective
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Protocol No
SWOG-S2012
Categories
Cancer, Colorectal, Other Gastrointestinal, Prostate, Pancreas/Liver, Ovary, Early Phase/Multiple Disease Site Cancers, Bladder, Prostate and Urologic Cancers, Gynecologic Cancers, Gastrointestinal Cancers

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors

Objective
To assess the safety, tolerability, dose-limiting toxicities (DLTs), and determine the maximum tolerated dose of INBRX-106 as a single agent administered as an intravenous infusion and in combination with pembrolizumab.
Protocol No
INHIBRX-PH1-INBRX-106
Categories
Cancer, Other Gastrointestinal, Gynecologic Cancers, Kidney, Melanoma, Skin, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gastrointestinal Cancers, Thoracic Cancers, Early Phase/Multiple Disease Site Cancers

A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors

Objective
The study is researching an investigational drug called REGN7075 by itself and in combination
with cemiplimab with or without chemotherapy.
Protocol No
REGENERON-R7075-ONC-2009
Categories
Cancer, Early Phase/Multiple Disease Site Cancers, Larynx, Gastrointestinal Cancers, Lip, Oral Cavity and Pharynx, Thoracic Cancers, Breast Cancers, Head and Neck Cancers, Skin Cancers